One Hotel Drive,

Boston,

MA,

US,

ZIP: 02128

Phone: +442031418700

From discovery to clinical development, the field of protein degradation is booming with excitement, with a whole host of investments and new companies joining the effort to successfully degrade unwanted or undrugged targets with key roles in a broad range of diseases from oncology to CNS, through to autoimmune.

Despite this, key challenges remain to rapidly and successfully discover novel and underexploited Ubiquitin E3 ligases. It is now critical that we fully understand the structure and function of E3s and accelerate ligand screening with new and improved tools to make this process less lengthy and risky for biopharma.

The 3rd Annual Ligase Targeting Drug Development Summit is returning with fresh understandings and data from the forerunners of the field and those who have recently joined the space. Together we will investigate ligase structural and functional biology, screening tools for optimal ligase and ligand identification, and uncover the novel assays that are aiding validation.

This dedicated forum will provide an unrivaled meeting point for industry leaders to strategically accelerate and de-risk the process of identifying, validating, and therapeutically leveraging cell and tissue-specific Ubiquitin E3 ligases for degradation or modulation of targets of interest.

URLs:
Tickets: https://go.evvnt.com/1450513-2?pid=1052
Brochure: https://go.evvnt.com/1450513-3?pid=1052

Prices:
FULL PACKAGE: Conference + Workshop Day OR Focus Day (Drug Developer Pricing): USD 4946.00,
Conference Only (Drug Developer Pricing): USD 2999.00,
FULL PACKAGE: Conference + Workshop Day OR Focus Day (Academic Rate): USD 4246.00,
Conference Only (Academic Rate): USD 2599.00,
FULL PACKAGE: Conference + Workshop Day OR Focus Day (Solution and Service Provider Pricing): USD 5846.00,
Conference Only (Solution and Service Provider Pricing): USD 3599.00

Speakers: Kirby Swatek, Principal Investigator, University of Dundee, Ian Churcher, Chief Scientific Officer, Amphista Therapeutics, David Duda, Senior Scientist, Johnson and Johnson, Abhishek Dogra, Director, Medicinal Chemistry, Foghorn Therapeutics, Yusuke Tominari, Co-Founder and Chief Executive Officer, FIMECS, Li Xiao, Computational Chemist, Merck, Seung Wook Yang, Scientist - Induced Proximity Platform, Ligase Biology Project Lead, Amgen, Satpal Virdee, MRC Investigator and Professor of Chemical Biology - MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Sarah Schlesiger, Principal Scientist - Medicinal Chemistry, EMD Serono, Sandra d'Azzo, Professor, St. Jude Children's Research Hospital, Sam Shrivastava, Chief Executive Officer, ASHA Therapeutics, Randolph Lopez, Co-Founder and Chief Technology Officer, A-Alpha Bio, Rainer Metcalf, Director - Computational Chemistry, ASHA Therapeutics, Ping Cao, Chief Executive Officer, Bridgene Biosciences, Peter Gareiss, Research Investigator, Arvinas, Nicholas Brown, Assistant Professor - Pharmacology, University of North Carolina - Chapel Hill, Nathaniel Henning, Scientist - Chemical Biology, Vicinitas Therapeutics, Monica Rodrigo-Brenni, Associate Director PROTAC Safety Science, AstraZeneca, Matt Clifton, Head of Structural and Biophysical Chemistry  Novartis, Kwok Chan, Investigator, GlaxoSmithKline, Kumar Suresh, Senior Director and Head of Drug Discovery, Progenra, Jo Hyunsun, Founder and Chief Executive Officer, Pin Therapeutics, Jing Liu, Vice President - Medicinal Chemistry, Cullgen, Jean Francois Brazeau, Senior Scientist - Medicinal Chemistry, Janssen, Gwenn Hansen, Chief Scientific Officer, Nurix Therapeutics, Gabriel Lander, Professor, Scripps, Eric Strieter, Professor, University of Massachusetts, Dafydd Owen, Senior Scientific Director - Medicinal Chemistry, Pfizer, Craig Stumpf, Principal Scientist, Plexium, Cheng Dong, Principal Investigator, Tianjin Medical University, Bonnie Tillotson, Senior Scientist, C4 Therapeutics